Intervertebral Disc Articles & Analysis
8 news found
Each subject received a single intradiscal injection of his or her assigned treatment into the target symptomatic lumbar intervertebral disc. In accordance with the trial design, subjects in all cohorts will be observed and evaluated for two years. ...
The pilot study will progress the development of its minimally-invasive chronic back pain treatment, DXM, which restores the function to intervertebral discs to relieve pain. By rehydrating the core (nucleus pulposus) of damaged spinal discs, the novel DXM polymer gel therapy restores their load-bearing properties, delaying or preventing surgical ...
“In preclinical observations of IDCT’s human Discogenic Cells in a canine disc degeneration model, I observed their ability to stop disc height degeneration while improving the structure of the intervertebral disc. ...
” Chronic low back pain is a widespread and often severely debilitating condition estimated to affect nearly 30 million people in the U.S., with over 70 percent failing to find adequate relief with conservative care and are not candidates for surgery. Until recently, the intervertebral discs have been thought to be the primary source of pain, referred to ...
Each subject received a single intradiscal injection of his or her assigned treatment into the target symptomatic lumbar intervertebral disc. In accordance with the trial design, subjects in all cohorts will be observed and evaluated for two years. ...
As a result, performance of periodic safety checks by an unblinded and independent body is essential to ensuring the ongoing safety of IDCT in a clinical setting.” About Degenerative Disc Disease DDD is a painful, chronic and progressive disease that is characterized by inflammation and breakdown of extracellular matrix within the intervertebral ...
Discogenic Cells are biomedically engineered progenitor cells derived from donated adult human intervertebral disc tissue to uniquely address the complex environment of the degenerated disc. ...
The pipeline comprises 4 initial products: AuriNovo™, a bioprinted ear to treat microtia (children born with undeveloped external ears), AnnuNovo™ to reduce reherniation of intervertebral discs, DiscNovo™ to replace degenerated intervertebral discs, and NasaNovo™, a bioprinted tissue to treat severe nasal ...